Xenotransplantation technology developer eGenesis has raised $125m in a series C round backed by Osage University Partners.

US-based gene-editing technology developer eGenesis closed a $125m series C round yesterday to further advance research conducted at Harvard University. Spinout-focused investment firm Osage University Partners backed the round, as did Leaps by Bayer and Fresenius Medical Care Ventures, respective vehicles for pharmaceuticals and chemicals producer Bayer and for kidney dialysis centres operator Fresenius Medical…

The rest of this content is only accessible to University Venturing: News, Data and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.